A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, intramuscular injection, antipsychotic agents, risperidone, paliperidone palmitate, dementia praecox, mental disorders, PANSS
Eligibility Criteria
Inclusion Criteria: A diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated types) according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV) for at least 1 year before the screening evaluation a total PANSS score of 60 to 120 at screening and baseline (pre-treatment) evaluations a body mass index (BMI [weight (kilograms)]/[height (meters)]²) of at least 15.0 kg/m² . Exclusion Criteria: A primary active DSM-IV Axis I diagnosis other than schizophrenia a decrease of 25% or more in the total PANSS score between screening and baseline evaluations a DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation a history of treatment resistance as defined by failure to respond to 2 adequate trials of different antipsychotic medications a woman who is pregnant, breast-feeding, or planning to become pregnant during the study period.